GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer

BACKGROUND: Vascular endothelial growth factor (VEGF) is a primary stimulant of angiogenesis under physiological and pathological conditions. Anti-VEGF therapy is a clinically proven strategy for the treatment of a variety of cancers including colon, breast, lung, and renal cell carcinoma. Since VEG...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynn, Kristi D, Udugamasooriya, D Gomika, Roland, Christina L, Castrillon, Diego H, Kodadek, Thomas J, Brekken, Rolf A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920882/
https://www.ncbi.nlm.nih.gov/pubmed/20673348
http://dx.doi.org/10.1186/1471-2407-10-397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920882/
https://www.ncbi.nlm.nih.gov/pubmed/20673348
http://dx.doi.org/10.1186/1471-2407-10-397

Ejemplares similares